United States· US:71287-119_224de0af-a3d4-4382-8271-4380843045be
YESCARTA
A axicabtagene ciloleucel product containing axicabtagene ciloleucel, registered in United States by Kite Pharma, Inc.. The same ATC class is registered in 13 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Axicabtagene ciloleucel is registered in 13 of 19 countries.
Countries holding a registration under ATC L01XL03 (axicabtagene ciloleucel), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 9 of them publish a price we can compare per daily dose
Axicabtagene ciloleucel · ATC L01XL03
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- AXICABTAGENE CILOLEUCEL
- Manufacturer
- Kite Pharma, Inc.
- Country
- United States (US)
- ATC code
- L01XL03
- ATC class
- Axicabtagene ciloleucel
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- August 9, 2026
Packs & prices · 1
- ndc1171287-119-02
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
58 interactions on record for axicabtagene ciloleucel.
Graded by severity as the source publishes them — 28 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Axicabtagene ciloleucel · interactions on record
58 records
- 28 severe
- 30 moderate
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Axicabtagene ciloleucel in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CanadaYESCARTAGILEAD SCIENCES CANADA INC
- SwitzerlandYescartaGilead Sciences Switzerland Sàrl
- CzechiaYESCARTAKite Pharma EU B.V., Hoofddorp
- SpainYESCARTA 0,4 - 2 x 10e8 CELULAS DISPERSION PARA PERFUSIONKite Pharma Eu B.V.
- FinlandYescartaKite Pharma EU B.V.
- FranceYESCARTA 0,4 - 2 x 100 000 000 cellules, dispersion pour perfusionKITE PHARMA EU (PAYS-BAS)
- BelgiumYescarta 0,4–2 x 10*8 cellsKite Pharma EU
- IrelandYescarta 0.4 – 2 × 108 cells dispersion for infusionKite Pharma EU B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Yescarta
- Liechtenstein · Yescarta
- Norway · Yescarta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ac608223-772f-489c-a9bf-d6f6d6253eee GET /v1/drugs/ac608223-772f-489c-a9bf-d6f6d6253eee?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "2000000",
"substance": "AXICABTAGENE CILOLEUCEL",
"productndc": "71287-119",
"dosage_form": "SUSPENSION",
"dea_schedule": null,
"strength_unit": "1/68mL",
"application_number": "BLA125643",
"marketing_category": "BLA"
}See everything about axicabtagene ciloleucel.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.